Clinical Guidelines for APL Treatment

PETHEMA Foundation

Status and phase: Unknown; Phase 4

Conditions: APL

Treatments: Drug: Atra; Drug: Idarubicin; Drug: methotrexate

Study type: Interventional

Funder types: Other

Identifiers

NCT02020161

PETHEMA LPA2012

Details and patient eligibility

About

Therapeutic guidelines for treatment of patients with de novo APL to be used by every institution that wants to follow them. All patients who are reported may be retrospectively analyzed

Enrollment: 200 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Genetic diagnosis of acute promyelocytic leukemia

Exclusion criteria

• No exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

200 participants in 1 patient group

ATRA-Idarubicin

Experimental group

Treatment:

Drug: Idarubicin

Drug: methotrexate

Drug: Atra